Analyzing Exicure (NASDAQ:XCUR) and Monte Rosa Therapeutics (NASDAQ:GLUE)

Monte Rosa Therapeutics (NASDAQ:GLUE) and Exicure (NASDAQ:XCUR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.

Earnings & Valuation

This table compares Monte Rosa Therapeutics and Exicure”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67 million	7.11	-$38.63 million	($1.76)	-5.85
Exicure	$500,000.00	13.76	-$4.95 million	($1.32)	-0.80

Exicure has lower revenue, but higher earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Monte Rosa Therapeutics and Exicure, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1	1	8	1	2.82
Exicure	1	0	0	0	1.00

Monte Rosa Therapeutics currently has a consensus target price of $27.62, suggesting a potential upside of 168.20%. Given Monte Rosa Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Monte Rosa Therapeutics is more favorable than Exicure.

Insider & Institutional Ownership

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Comparatively, 52.8% of Exicure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Monte Rosa Therapeutics and Exicure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
Exicure	N/A	-237.91%	-61.98%

Risk & Volatility

Monte Rosa Therapeutics has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, Exicure has a beta of 3.64, indicating that its share price is 264% more volatile than the S&P 500.

Summary

Monte Rosa Therapeutics beats Exicure on 8 of the 15 factors compared between the two stocks.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

About Exicure

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.